Brown Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $209K | Buy |
749
+19
| +3% | +$5.47K | ﹤0.01% | 1321 |
|
|
2025
Q4 | $221K | Sell |
730
-19
| -3% | -$5.93K | ﹤0.01% | 1312 |
|
|
2025
Q3 | $210K | Sell |
749
-178
| -19% | -$48.4K | ﹤0.01% | 1321 |
|
|
2025
Q2 | $224K | Sell |
927
-157
| -14% | -$37.1K | ﹤0.01% | 1268 |
|
|
2025
Q1 | $264K | Sell |
1,084
-344
| -24% | -$103K | ﹤0.01% | 1177 |
|
|
2024
Q4 | $469K | Sell |
1,428
-870
| -38% | -$295K | ﹤0.01% | 1035 |
|
|
2024
Q3 | $769K | Sell |
2,298
-1,222
| -35% | -$388K | ﹤0.01% | 854 |
|
|
2024
Q2 | $961K | Sell |
3,520
-12,922
| -79% | -$3.76M | ﹤0.01% | 780 |
|
|
2024
Q1 | $5.69M | Buy |
16,442
+873
| +6% | +$287K | 0.01% | 477 |
|
|
2023
Q4 | $5.03M | Sell |
15,569
-940,163
| -98% | -$295M | 0.01% | 484 |
|
|
2023
Q3 | $343M | Buy |
955,732
+28,724
| +3% | +$11.1M | 0.56% | 46 |
|
|
2023
Q2 | $351M | Buy |
927,008
+80,607
| +10% | +$32.8M | 0.55% | 48 |
|
|
2023
Q1 | $405M | Buy |
846,401
+25,516
| +3% | +$11.9M | 0.69% | 38 |
|
|
2022
Q4 | $345M | Buy |
820,885
+45,173
| +6% | +$18.2M | 0.64% | 41 |
|
|
2022
Q3 | $324M | Buy |
775,712
+193,896
| +33% | +$96.7M | 0.63% | 42 |
|
|
2022
Q2 | $288M | Buy |
581,816
+80
| +0% | +$41.7K | 0.54% | 48 |
|
|
2022
Q1 | $328M | Buy |
581,736
+42,375
| +8% | +$25.5M | 0.49% | 50 |
|
|
2021
Q4 | $408M | Sell |
539,361
-31,847
| -6% | -$23.8M | 0.51% | 54 |
|
|
2021
Q3 | $426M | Buy |
571,208
+1,976
| +0.3% | +$1.48M | 0.63% | 47 |
|
|
2021
Q2 | $367M | Buy |
569,232
+37,045
| +7% | +$22.5M | 0.55% | 54 |
|
|
2021
Q1 | $304M | Buy |
532,187
+56,515
| +12% | +$33.5M | 0.52% | 55 |
|
|
2020
Q4 | $277M | Buy |
475,672
+10,263
| +2% | +$5.84M | 0.49% | 56 |
|
|
2020
Q3 | $240M | Buy |
465,409
+50,277
| +12% | +$25.5M | 0.5% | 55 |
|
|
2020
Q2 | $187M | Buy |
415,132
+70,846
| +21% | +$31.3M | 0.44% | 57 |
|
|
2020
Q1 | $121M | Buy |
344,286
+115,774
| +51% | +$42.6M | 0.37% | 59 |
|
|
2019
Q4 | $84.6M | Buy |
+228,512
| New | +$80.6M | 0.21% | 96 |
|
|
2019
Q2 | – | Sell |
-1,226
| Closed | -$376K | – | 1056 |
|
|
2019
Q1 | $376K | Buy |
1,226
+159
| +15% | +$42.9K | ﹤0.01% | 1067 |
|
|
2018
Q4 | $248K | Buy |
1,067
+139
| +15% | +$37.3K | ﹤0.01% | 1120 |
|
|
2018
Q3 | $291K | Buy |
928
+18
| +2% | +$5.59K | ﹤0.01% | 1151 |
|
|
2018
Q2 | $262K | Sell |
910
-40
| -4% | -$11K | ﹤0.01% | 1149 |
|
|
2018
Q1 | $238K | Buy |
+950
| New | +$242K | ﹤0.01% | 1059 |
|
Other funds holding BIO
VCM
VPM
AI
Brown Advisory's BIO Position: Q1 2026 in Review
Brown Advisory increased its Bio-Rad Laboratories Class A (BIO) stake by 2.6% in Q1 2026, buying an estimated $5.47K and bringing the position to 749 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.
Brown Advisory first reported a position in BIO in Q1 2018 and has held it in 31 quarters since. The position peaked at $426M in Q3 2021. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- Brown Advisory held 749 shares of Bio-Rad Laboratories Class A worth $209K as of Q1 2026.
- Brown Advisory bought 19 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $5.47K.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #1321 holding.
- Brown Advisory first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and has held it in 31 quarters since.
- Brown Advisory's Bio-Rad Laboratories Class A position peaked at $426M in Q3 2021.
- 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.